These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21104392)

  • 21. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
    Després JP; Lemieux I; Alméras N
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The endocannabinoid system: a promising target for the management of type 2 diabetes.
    Scheen AJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications.
    Viveros MP; de Fonseca FR; Bermudez-Silva FJ; McPartland JM
    Endocr Metab Immune Disord Drug Targets; 2008 Sep; 8(3):220-30. PubMed ID: 18782018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
    Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
    FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CB(1) receptor antagonism: biological basis for metabolic effects.
    Di Marzo V
    Drug Discov Today; 2008 Dec; 13(23-24):1026-41. PubMed ID: 18824122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
    Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
    Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in the Peripheral Endocannabinoid System as a Risk Factor for the Development of Eating Disorders.
    Capasso A; Milano W; Cauli O
    Endocr Metab Immune Disord Drug Targets; 2018; 18(4):325-332. PubMed ID: 29437028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The endocannabinoid system: a new approach to control cardiovascular disease.
    Cannon CP
    Clin Cornerstone; 2005; 7(2-3):17-26. PubMed ID: 16473257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The endocannabinoid system].
    Sudano I; Périat D; Noll G
    Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 32. Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.
    Cota D; Genghini S; Pasquali R; Pagotto U
    J Endocrinol Invest; 2003 Oct; 26(10):1041-4. PubMed ID: 14759080
    [No Abstract]   [Full Text] [Related]  

  • 33. Endocannabinoid system and cardio-metabolic risk.
    Loh KY; Kew ST
    Med J Malaysia; 2008 Oct; 63(4):348-50; quiz 351. PubMed ID: 19385504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
    Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
    Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
    Deedwania P
    Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocannabinoids and the control of energy homeostasis.
    Kunos G; Osei-Hyiaman D; Liu J; Godlewski G; Bátkai S
    J Biol Chem; 2008 Nov; 283(48):33021-5. PubMed ID: 18694938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The endocannabinoid system as a target for obesity treatment.
    Aronne LJ; Pagotto U; Foster GD; Davis SN
    Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity.
    Heyman E; Gamelin FX; Aucouturier J; Di Marzo V
    Obes Rev; 2012 Dec; 13(12):1110-24. PubMed ID: 22943701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 40. The challenge of treating obesity: the endocannabinoid system as a potential target.
    Isoldi KK; Aronne LJ
    J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.